Molecular diagnostics of genital tuberculosis. Introduction

Similar documents
Characteristics of Mycobacterium

TB the basics. (Dr) Margaret (DHA) and John (INZ)

MULTIDRUG- RESISTANT TUBERCULOSIS. Dean Tsukayama Hennepin County Medical Center Hennepin County Public Health Clinic

Search for a low-cost screening test for female genital tuberculosis: A study in a tertiary care level hospital of West Bengal

Genital Tuberculosis in Infertile Women: Assessment of Endometrial TB PCR Results with Laparoscopic and Hysteroscopic Features

INTENSIFIED TB CASE FINDING

International Journal of Medical Science and Education pissn eissn

Frances Morgan, PhD October 21, Comprehensive Care of Patients with Tuberculosis and Their Contacts October 19 22, 2015 Wichita, KS

Latent Tuberculosis Infections Controversies in Diagnosis and Management Update 2016

Fundamentals of Tuberculosis (TB)

Antimycobacterial drugs. Dr.Naza M.Ali lec Dec 2018

Summary of Key Points WHO Position Paper on BCG Vaccine, February 2018

Improved diagnosis of extrapulmonary tuberculosis by antigen detection using immunochemistry-based assay. Tehmina Mustafa

Diagnostic Value of Elisa Serological Tests in Childhood Tuberculosis

Questions and Answers Press conference - Press Centre Room 3 Wednesday 16 August 2006, 14.00hrs

TB & HIV CO-INFECTION IN CHILDREN. Reené Naidoo Paediatric Infectious Diseases Broadreach Healthcare 19 April 2012

CMH Working Paper Series

Diagnosis of drug resistant TB

Tuberculosis 6/7/2018. Objectives. What is Tuberculosis?

CULTURE OR PCR WHAT IS

MODULE ONE" TB Basic Science" Treatment Action Group TB/HIV Advocacy Toolkit

Identifying TB co-infection : new approaches?

Treatment of Active Tuberculosis

TB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai

TB 101 Disease, Clinical Assessment and Lab Testing

Tuberculosis. New TB diagnostics. New drugs.new vaccines. Dr: Hussein M. Jumaah CABM Mosul College of Medicine 23/12/2012

Tuberculosis. Impact of TB. Infectious Disease Epidemiology BMTRY 713 (A. Selassie, DrPH)

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

Principle of Tuberculosis Control. CHIANG Chen-Yuan MD, MPH, DrPhilos

CHAPTER 3: DEFINITION OF TERMS

A Review on Prevalence of TB and HIV Co-infection

of clinical laboratory diagnosis in Extra-pulmonary Tuberculosis

Tuberculosis Tools: A Clinical Update

Research in Tuberculosis: Translation into Practice

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

Online Annexes (2-4)

Molecular diagnosis of MDR-TB using GenoType MTBDRplus 96 assay in Ibadan, Nigeria

4/25/2012. The information on patterns of infection and disease can assist in: Assessing current and evolving trends in TB

Pathology of pulmonary tuberculosis. Dr: Salah Ahmed

Tuberculosis Populations at Risk

APSR RESPIRATORY UPDATES

Tuberculosis Epidemiology

Comparison of conventional methods with automation and card ELISA test for the diagnosis of Pulmonary Tuberculosis

Hysteroscopy findings and its correlation with latent endometrial tuberculosis in infertility

Programmatic management of LTBI : a two pronged approach for ending the TB epidemic. Haileyesus Getahun Global TB Programme WHO/HQ

Current Therapy and Surgery for Urogenital Tuberculosis

DRUG RESISTANCE IN TUBERCULOSIS

ESCMID Online Lecture Library. by author

TB In Detroit 2011* Early TB: Smudge Sign. Who is at risk for exposure to or infection with TB? Who is at risk for TB after exposure or infection?

Pelvic Inflammatory Disease (PID) Max Brinsmead PhD FRANZCOG July 2011

Where are we heading?

NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL

TB NAAT testing at the Los Angeles County Public Health Laboratory

Descriptive Epidemiology Project: Tuberculosis in the. United States. MPH 510: Applied Epidemiology. Summer A 2014

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

New Tuberculosis Guidelines. Jason Stout, MD, MHS

Identification of antigens and antibodies in body fluids Delia Goletti, MD, PhD

Global, National, Regional

Mycobacterium tuberculosis. Lecture (14) Dr.Baha, AL-Amiedi Ph. D.Microbiology

Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

TB Laboratory for Nurses

Stacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona

Diagnosis of Tuberculosis by GeneXpert MTB/RIF Assay Technology: A Short Review

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

Press Release: Embargo in place until Monday, February 19 th, 2018 I 6:00 Eastern standard Time (11GMT)

Diagnosing Inaccuracy: New WHO Policy Shift to End Ineffective TB Practices

Appendix C. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Rapid PCR TB Testing Results in 68.5% Reduction in Unnecessary Isolation Days in Smear Positive Patients.

International Journal of Health Sciences and Research ISSN:

SWABCHA Fact Sheet: Tuberculosis (TB)

CHAPTER:1 TUBERCULOSIS. BY Mrs. K.SHAILAJA., M. PHARM., LECTURER DEPT OF PHARMACY PRACTICE, SRM COLLEGE OF PHARMACY

Evaluation of Xpert MTB/ RIF Assay for the Detection of Female Genital Tuberculosis in a Tertiary Care Center- A Descriptive Cross-sectional Study

Correlation Of Immunological And Pathological Parameters In Extra-Pulmonary Tuberculosis

Evaluation of the Microscopic-Observation. Drug-Susceptibility Assay Drugs Concentration for Detection Of Multidrug-Resistant Tuberculosis

Medical Bacteriology- Lecture 10. Mycobacterium. Actinomycetes. Nocardia

TB in Children. Rene De Gama Block 10 Lectures 2012

Global, National, Regional

Drug Resistant Tuberculosis Biology, Epidemiology and Control Dr. Christopher Dye

Mycobacteria & Tuberculosis PROF.HANAN HABIB & PROF ALI SOMILY DEPRTMENT OF PATHOLOGY, MICROBIOLOGY UNIT COLLEGE OF MEDICINE

Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

Appendix B. Recommendations for Counting Reported Tuberculosis Cases (Revised July 1997)

TUBERCULOSIS IN HEALTHCARE SETTINGS Diana M. Nilsen, MD, FCCP Director of Medical Affairs, Bureau of Tuberculosis Control New York City Department of

Ken Jost, BA, has the following disclosures to make:

Global epidemiology of drug-resistant tuberculosis. Factors contributing to the epidemic of MDR/XDR-TB. CHIANG Chen-Yuan MD, MPH, DrPhilos

Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it

Report on WHO Policy Statements

Chapter 4 Diagnosis of Tuberculosis Disease

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

GUIDELINES FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF LEPROSY EXECUTIVE SUMMARY

Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014

Revised National Tuberculosis Control Programme

HIV AIDS and Other Infectious Diseases

LESSON 4.4 WORKBOOK. How viruses make us sick: Viral Replication

LESSON 4.6 WORKBOOK. Designing an antiviral drug The challenge of HIV

Biology and Medicine

World Journal of Pharmaceutical and Life Sciences WJPLS

What is tuberculosis? What causes tuberculosis?

Transcription:

INTRODUCTION

Introduction Mycobacterium tuberculosis, the etiological agent for tuberculosis, has been extensively studied for over a century now. But the disease sill remains a major public health concern today in the 21 st century. Despite the availability of anti-tubercular chemotherapy tuberculosis still remains a major health problem and is the leading cause of morbidity and mortality in many developing/ resource-poor countries. Despite the efforts that are being made to control tuberculosis worldwide, countless numbers of people die with every passing year (1). More than a decade ago, tuberculosis was identified as a global health emergency. According to the WHO report on global tuberculosis control 2011, India and China together account for 40% of the world s TB burden (1). In 2010, there were 8.8 million (range, 8.5 9.2 million) incident cases of tuberculosis, 1.1 million (range, 0.9 1.2 million) deaths from TB among HIV-negative people and an additional 0.35 million (range, 0.32 0.39 million) deaths from HIV-associated TB (1). Control of the disease is complicated by the fact that one-third of the world s population is latently infected with tuberculosis. An estimated 5-10% of the latently infected population develops active disease during its lifetime while the rest act as reservoir of pathogen thus making the disease control a significant challenge (2). The only vaccine, Bacillus Calmette-Guerin vaccine, offers some protection against several forms of tuberculosis most often contracted by children, but is not effective against adult pulmonary TB. Tuberculosis can be triggered by anything that reduces a person s immunity, such as HIV-infection, diabetes, kidneys failure, or cancer treatment. Children are also more at risk of developing active TB than adults, because their immune systems are not fully developed. Efforts in averting the disease have further been impeded by the synergistic relationship between tuberculosis and HIV, as tuberculosis, being an opportunistic infection worsens the immunological suppression in HIV patients. HIV-infected people are anywhere from 50 to 400 times more likely than their HIV-uninfected counterparts to develop active TB disease. In addition, the PhD Thesis 1 University of Delhi, Delhi

difficulty in co administration of the anti-tb and anti-hiv drugs as a result of drugdrug interactions is well established. In addition, tuberculosis is difficult to diagnose in HIV-positive subjects as smear microscopy, a test widely used in developing countries fails to detect TB in 80% HIV-positive cases. Spread of drug resistant strains poses new challenges for prevention and control of this deadly disease as the present therapy fails to work on the drug resistant strains. Unless we act promptly and aggressively, this emerging global health threat will spiral, threatening to return to the pre-antibiotic era. Failure to develop programs to diagnose and treat such patients now will be more costly in the future, leading to increased incidence, greater residence, and more deaths. Non-availability of domestic funding in developing countries is again a fall back in the disease control. Early, accurate diagnosis and immediate curative treatment, under proper supervision to ensure that drugs are taken for the appropriate duration, is the key to disease control. Among various clinical presentations of tuberculosis, female genital tuberculosis poses serious concern throughout the world because of various associated complications like oligomenorrhea, amenorrhea, primary or secondary infertility, chronic pelvic pain, pelvic mass and significant mortality (3-7). The disease is being increasingly recognised as a notable cause of infertility in recent years. Infertility is otherwise a common problem but only the couples afflicted with it can understand the social stigma, psychological stress and trauma behind it. The true incidence of the disease remains unknown as the disease poses diagnostic difficulties mainly because the primary symptoms are usually non-characteristic (8, 9). Infertility is a well-known sequela (10). Early diagnosis invariably helps to speed up the decision-making process and markedly reduces the time lag in starting anti-tubercular therapy. Although the reported incidence of genital tuberculosis in Asian and western countries varies between 0.69% in Australia and 17.4% in India, the actual incidence may be higher because a large proportion of cases go unreported due to lack of sensitive and specific investigations (11,12). Factors such as poverty, homelessness, a poorly functioning national tuberculosis program and dismantling of public health infrastructure have significantly contributed to the worsening situation (13). Prevalence of female genital PhD Thesis 2 University of Delhi, Delhi

tuberculosis varies widely from 0.69% in Australia to 19% in India in women of reproductive age group, mostly as a secondary complication to the primary focus elsewhere in the body (14). The most commonly affected organs are the fallopian tubes and endometrium, followed by the ovaries, cervix, vagina and vulva, and it is often associated with tubal blockage and pelvic, peritubal and perihepatic adhesions (Fitz Hugh Curtis syndrome) (5, 14-16). Female genital tuberculosis commonly causes caseation and ulceration of the endometrium, resulting in destruction and partial or total obliteration of uterine cavity leading to Asherman s syndrome (8, 17). In India, 5 16% infertility is reportedly caused by tuberculosis, but the actual incidence rate may be underreported due to asymptomatic presentation of the disease and paucity of investigations (17). Effective management involves rapid, accurate diagnosis and early anti-tubercular treatment. The diagnosis of tuberculosis still relies on acid fast bacilli (AFB) microscopy and culture, despite the fact that both techniques suffer several diagnostic lacunae, as reported earlier (18). In samples derived from extrapulmonary sites that are often paucibacillary in nature, smear microscopy offers low sensitivity, requiring 10 4 bacilli/ml for detection. Culture, although being the gold standard, requires a minimum of 10 100 bacilli/ml and a long incubation period (by rapid test the earliest that mycobacteria can be detected is within twelve days) causing delay in diagnosis and treatment. Histopathological examination by haematoxylin and eosin for granulomatous tissue reactions compatible with tuberculosis infection is usually inconclusive, as reported earlier (19). Over the last decade, polymerase chain reaction (PCR) has emerged as a rapid, sensitive and specific molecular method for detection of mycobacterial DNA by amplifying 65 kda protein-encoding gene, 38 kda antigen coding gene, the IS6110 and mpt64 gene in both pulmonary and extrapulmonary samples, as reported by various authors (14,15,20,21). Subclinical disease or latent tuberculosis infection might give a positive result in PCR, but this is considered insignificant as prompt diagnosis is essential for averting permanent damage to genital organs and consequent infertility. Endoscopic procedures like laparoscopy and hysteroscopy are widely used for investigation of infertile women (22-24). Their role in PhD Thesis 3 University of Delhi, Delhi

the diagnosis of genital tuberculosis is well established. However, subclinical, latent or early stage infection may be overlooked during the procedure. A positive laboratory test may thus be helpful in timely diagnosis before extensive damage occurs. PCRs for detection and identification of mycobacteria in clinical specimens have been developed and evaluated (23,24), but mrna-based assay offers great promise in differentiating between live and dead bacilli as the average half-life of bacterial mrna is 3 min (25). Thus as mrna is more easily destroyed than DNA, it can distinguish viable from non viable organism. Table 1: Comparison of various diagnostic modalities for diagnosis of genital tuberculosis Method No of Time Advantages Disadvantages Organisms Reqd AFB smear/ 10,000 org/ml 1 day Cost effective Low sensitivity; Microscopy Takes less time requires high bacterial count Culture LJ 10-100 org/ml 6 wks Old-time Long time required Gold Standard Lacks sensitivity Very Specific Culture BACTEC 10-100 org/ml 2 wks Higher sensitivity High cost and use 460 TB system & Specificity of radioactives Lacks sensitivity MOLECULAR METHODS (DNA fingerprinting- Expensive based diagnostics) i) DNA-PCR 1-10 org/ml ~6-8 hrs Highly Sen/Specific Highly ii) mrna-rt PCR 1-10 org/ml ~1 day Unique for viability skilled iii) Gene Seq for 1-10 org/ml ~2 day Ultimate method for personnel Mutation analysis confirmation/ required Drug-resistance gene The emergence of resistance to anti-tuberculosis drugs is a matter of serious concern worldwide and has been reported by several studies (26-28). The situation is aggravated by the increasing incidence of multi-drug resistant (MDR) Mycobacterium tuberculosis strains that are defined as being resistant to at least Rifampicin (RMP) and Isoniazid (INH), the drugs which comprise the backbone of anti-tuberculosis chemotherapy. Rifampicin, which is a semi-synthetic derivative of Rifamycin, is one of the most potent anti-tuberculosis drugs and has a highly effective bactericidal activity against Mycobacterium tuberculosis which has made it the principle drug in first line of TB medication. Rifampicin binds to the subunit of ribonucleic acid (RNA) polymerase PhD Thesis 4 University of Delhi, Delhi

resulting in inhibition of transcription initiation. Presence of Rifampicin resistance increases the likelihood of MDR-TB because Mycobacterium tuberculosis strains resistant to rifampicin are more likely to be resistant to several other anti-tb drugs (29). Table 1 shows comparison of various diagnostic tests for genital tuberculosis. The molecular basis of resistance to anti-tb drugs is becoming better understood with time. RMP resistance is essentially mediated by the mutation in rifampicin resistance determining region (RRDR) corresponding to codon position 507 533 of rpo B gene (30, 31). While on the other hand, INH resistance is apparently controlled by a more complex genetic system that involves several genes, namely kat G, inh A, kas A and ahp C (32). However, extensive studies have demonstrated that INH resistance is most frequently associated with mutation in kat G, a gene that encodes the catalase peroxidase enzyme in Mycobacterium tuberculosis and inh A gene responsible for inhibition of mycolic acid synthesis in the bacteria (32). Sequence-based monitoring of mutation(s) in the defined targets of drug-resistance genes may improve the treatment and decision-making process. Very limited studies have been carried-out in India in case of genital tuberculosis. Hence, understanding molecular insight is important for understanding the disease, diagnostics, therapeutics and management. Based on the aforesaid facts, we undertook the present study to assess the utility of PCR in definitive diagnosis of tuberculosis in Indian infertility patients in conjunction with endoscopic procedures laparoscopy and/hysteroscopy and conventional tests (smear and culture based on the radiometric BACTEC system). Utility of RT-PCR in distinguishing active cases from the past infection will also be evaluated. Also, considering the clinical importance of multi-drug resistance in genital tuberculosis we plan to investigate all genital tuberculosis positive cases for Rifampicin and Isoniazid resistance by automated DNA sequencing of rpo B, kat G and inh A genes. PhD Thesis 5 University of Delhi, Delhi

Lacunae in current knowledge on genital tuberculosis The actual incidence of genital TB in the general population cannot be accurately measured, as most of the patients are asymptomatic and may remain undiscovered. The diagnosis thus requires high index of suspicion. Early diagnosis of genital TB and its treatment in young patients is essential and may improve the prospects of care before the tubes are damaged beyond recovery. The diagnosis of tuberculosis still relies on acid fast bacilli (AFB) microscopy and culture, despite the fact that both techniques suffer several diagnostic lacunae. In samples derived from extrapulmonary sites that are often paucibacillary in nature, smear microscopy offers low sensitivity, requiring 10 4 bacilli/ml for detection. Culture, although being the gold standard, requires a minimum of 10 100 bacilli/ml and a long incubation period (by rapid test the earliest that mycobacteria can be detected is within 12 days) causing delay in diagnosis and treatment. Histopathological examination for granulomatous tissue reactions compatible with tuberculosis infection is usually inconclusive. The commonly used Laparoscopy (the so-called Clinical Gold Standard) may be indicative only and that too may help at later stage and hence not conclusive. Over the last decade, polymerase chain reaction (PCR) has emerged as a rapid, sensitive and specific molecular method for detection of mycobacterial DNA by amplifying 65 kda protein-encoding gene, 38 kda antigen coding gene, IS6110 and mpt64 gene in both pulmonary and extra-pulmonary samples, as reported by various authors. Subclinical disease or latent tuberculosis infection might give a positive result in PCR, but this is considered insignificant as prompt diagnosis is essential for averting permanent damage to genital organs and consequent infertility. Despite significant diagnostic promise of DNA-PCR for confirming clinical diagnosis of genital tuberculosis, this method is not useful for differentiating between active and latent or dormant cases. In some other infectious diseases, mrna-based methods have been shown to act as an important tool for pinpointing active disease; it would be PhD Thesis 6 University of Delhi, Delhi

worthwhile to evaluate mrna-based RT-PCR or Real-time PCR for confirming the active cases of genital tuberculosis. However, only limited studies have been carriedout worldwide, particularly on the innovative diagnostics and drug-resistance components of female genital tuberculosis; Indian data on the subject is almost negligible excepting couple of recent reports on limited samples. Molecular insight directed towards understanding an evolving innovative disease diagnostics, detection of active cases earlier than later, and keeping a vigil over the possible drug-resistance mutation(s) through gene-fingerprinting seemed very important to supplement/fill the existing gap in knowledge better management of female genital tuberculosis that may prove to be a central dogma in reducing incidence of tuberculosis-associated female infertility in India. Present study was therefore intended to characterize 65kDa antigen coding gene by PCR (DNA PCR) in diagnosis of genital tuberculosis, assess the utility of mrna-based PCR (RT-PCR) followed by gene sequencing for differentiating between active and latent cases of genital tuberculosis; and lastly to unveil mutations in the drug resistance genes (rpo B, kat G and inh A) through DNA signature sequences associated with resistance to Rifampicin and Isoniazid. PhD Thesis 7 University of Delhi, Delhi